REGENXBIO (RGNX) Set to Announce Quarterly Earnings on Wednesday

REGENXBIO (NASDAQ:RGNX) is set to announce its earnings results after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($1.16) per share for the quarter.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The firm had revenue of $22.30 million for the quarter, compared to analysts’ expectations of $22.97 million. During the same quarter last year, the company earned ($1.66) EPS. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. On average, analysts expect REGENXBIO to post $-5 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

REGENXBIO Stock Up 1.9 %

Shares of RGNX opened at $9.01 on Thursday. REGENXBIO has a 52-week low of $8.81 and a 52-week high of $28.80. The firm’s fifty day moving average is $10.98 and its two-hundred day moving average is $12.84. The stock has a market cap of $443.80 million, a PE ratio of -1.50 and a beta of 1.21.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Raymond James reaffirmed an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research note on Thursday, October 10th. Barclays lowered their target price on shares of REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Chardan Capital reaffirmed a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research note on Tuesday, October 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $39.00 target price on shares of REGENXBIO in a research note on Wednesday, September 4th. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus price target of $35.45.

Insider Activity at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the sale, the director now directly owns 11,286 shares in the company, valued at approximately $114,101.46. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 13.13% of the stock is owned by insiders.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.